Pharmacists should be aware of the new data and recommendations surrounding novel agents and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.

It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.

To help patients have the best outcomes possible, clinicians need education on selection of therapy (high-intensity, low-intensity, or targeted) and on how best to manage toxicities and provide supportive care.

Clinicians must understand the treatment evolution and guidelines for when to administer two-, three-, or four drug regimens as initial or subsequent therapy in context of the patient's therapeutic and disease history. In addition, it is important for clinicians to educate patients about their different treatment options (e.g., administration and adverse events) and discuss patient preferences and individual circumstances that may affect treatment recommendations.